Effect of interferon therapy on hepatitis B virus related membranous nephropathy associated with focal segmental glomerulosclerosis

Japanese Journal of Nephrology

Volumn 43, Issue 2, 2001, Pages 76-81

  Iwata, Yasunori ^a   Wada, Takashi ^b   Yoshimoto, Keiichi ^b   Sakai, Norihiko ^b   Shimizu, Miho ^b   Furuichi, Kengo ^b   Hisada, Yukimasa ^b   Kobayashi, Ken Ichi ^b   Yokoyama, Hitoshi ^a  

^a KANAZAWA UNIVERSITY   (Japan)

^b NONE

Author keywords

Hepatitis B virus, membranous nephropathy, focal segmental glomerulosclerosis, membrano proliferative glomerulonephritis, interferon

Indexed keywords

ALPHA2B INTERFERON; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DNA POLYMERASE; HEPATITIS B(E) ANTIGEN;

ADULT; ARTICLE; CASE REPORT; CHRONIC HEPATITIS; DRUG EFFECT; FOCAL GLOMERULOSCLEROSIS; HEPATITIS B; HUMAN; HUMAN TISSUE; KIDNEY BIOPSY; LIVER BIOPSY; MALE; MEMBRANOUS GLOMERULONEPHRITIS; PROTEINURIA;

ADULT; CARRIER STATE; GLOMERULONEPHRITIS, MEMBRANOUS; GLOMERULOSCLEROSIS, FOCAL SEGMENTAL; HEPATITIS B; HUMANS; INTERFERON ALFA-2B; MALE;

EID: 0035082832     PISSN: 03852385     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (29)

1. Gilbert RD, Wiggelinkhuizen J. The clinical course of hepatitis B virus-associated nephropathy. Pediatr Nephrol 1994 ; 8 : 11-4.
2. Lai KN. The therapeutic dilemma of the usage of corticosteroid in patients with membranous nephropathy and persistent hepatitis B and surface antigenemia. Nephron 1990 ; 54 : 12-7.
3. Lai KN. Membranous nephropathy related to hepatitis B virus in adults. N Eng J Med 1991 ; 324 : 1457-63.
4. Takeda S, Kida H, Katagiri M, Yokoyama H, Abe T, Hattori N. Characteristics of glomerular lesions in hepatitis B virus infection. Am J Kidney Dis 1988 ; 11 : 55-62.
5. Iida H, Izumino K, Asaka M, Fujita M, Takata M, Sasayama S. IgA nephropathy and hepatitis B virus : IgA nephropathy unrelates to hepatitis B surface antigenemia. Nephron 1990 ; 54 : 18-20.
6. Greenberg HB, Pollard RB, Luteick LI, Gregory PB. Effect of human leucocyte interferon on hepatitis B virus infection in patients with chronic active hepatitis. N Engl J Med 1976 ; 295 : 517-22.
7. Chin YL, Chiou CL, Gwong JC, Chwan CK. Defect of cell-mediated immune response against hepatitis B virus : An indication for pathogenesis of hepatitis-B-virus-associated membranous nephropapthy. Nephron 1997 : 76 : 176-85.
8. Holdworth SR, Kithcing AR, Tipping PG. Th1 and Th2 T helper cell subsets affect patterns of injury and outcomes in glomerulonephritis. Kidney Int 1999 ; 55 : 1198-216.
9. Oliveria DBG. Membranous nephropathy : an IgG4-mediated disease. Lancet 1998 ; 351 : 670-71.
10. Wong SN, Yu EC, Lok AS, Chang KW, Lau YL. Interferon treatment for hepatitis B-associated membranous glomerulonephritis in two Chinese children. Pediatr Nephrol 1992 ; 6 : 417-20.
11. Lidoman C, Magnius L, Dorder H, Weiland O. IFNα-2b treatment in an HIV-infected patient with hepatitis B virus induced nephrotic syndrome. Scand J Infect Dis 1993 ; 25 : 133 5.
12. Shapiro RJ, Steinbrecher UP, Magil A. Remission of nephrotic syndrome of HBV-associated membranous glomerulopathy following treatment with interferon. Am J Nephrol 1995 ; 15 : 343-7.
13. Lin CY. Treatment of hepatitis B virus-associated membranous nephropathy with recombinant α-Interferon. Kidney Int 1995 ; 47 : 225-30.
14. Conjeevaran HS, Hoofngle JH, Austin HS, Park Y, Fried MW, Di Bisceglie AM. Long-term outcome of hepatitis B virus-related glomerulonephritis after therapy with interferon α. Gastroenterology 1995 ; 109 : 540-6.
15. Chung DR, Yang WS, Kim SB, Yu E, Chung YH, Lee Y, Park JS. Treatment of hepatitits B virus associated glomerulonephritis with recombinant human α-interferon. Am J Nephrol 1997 ; 17 : 112-7.
16. Lopes Neto EP, Lopws LV, Kirsztajn GM, Cruz CN, Ferraz ML, Silva AE. α-interferon therapy for HBV-related glomerulonephritis. Rev Paul Med 1998 ; 116 : 1823-5.
17. Nasir A, Mark P, Alexander T, Green S. Successful treatment of hepatitis B virus-associated membranoproliferative glomerulonephritis with α-interferon. Nephrol Dial Transplant 1999 ; 14 : 1272-5.
18. Radha D, Harbir K, Gautam D, Kusum J, Yogesh C, Vinay S. Remission of HBV-related mesangio-proliferative glomerulonephritis after interferon therapy. Nephrol Dial Transplant 1999 ; 14 : 176-8.
19. de Man A, Schalm W, van der Heijden J. Improvement of hepatitis B-associated glomerulonephritis after antiviral combination therapy. J Hepatol 1989 ; 8 : 367-72.
20. Mukaida N, Harada A, Matsushima K. Interleukin-8 (IL-8) and monocyte chemotactic and activating factor(MCAF/ MCP-I), chemokines essentially involved in inflammatory and immune reactions. Cytokine Growth Factor Rev 1998 ; 9 : 9-23.
21. Wakai S, Alex B, Magil AB. Focal glomerulosclerosis in idiopathic membranous glomerulonephritis. Kidney Int 1992 ; 41 : 428-34.
22. Gerjan N, Paul EJ, Dick Z. Specific pharmacologic approaches to clinical renoprotection In : Brenner BM, Rector FC, The Kidney 6th ed. Philadelphia : WB Saunders, 1998 : 2341-72.
23. Wolf G. Angiotensin as a renal growth promoting factor. Adv Exp Med Biol 1995 ; 377 : 225-36.
24. Remuzzi A, Ruggenenti P, Mosconi L, Remuzzi G. Effect of low-dose enalapril on glomerular size selectivity in human diabetic nephrology. J Nephrol 1993 ; 6 : 36-43.
25. da Boer E, Navis G, Wapstra FH, de Jong PE de Zeeuw D Effect of proteinuria reduction on prevention of focal glomerulosclerosis by angiotensin-converting enzyme inhibition is modifiable Kidney Int (Suppl 71) 1999 ; 56 : S42-6.